Eiger BioPharmaceuticals, Inc. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Palo Alto, CA
SEC filing record 1 source field available
Fiscal year end
31 December
Eiger BioPharmaceuticals, Inc. has filed 694 SEC EDGAR filings since 05 Oct 2004

SEC filing history

Showing 476-500 of 687 matching filings.

Per page
25
Current page
20
3

FORM 3 SUBMISSION

Filing date
25 Mar 2016
Reporting date
22 Mar 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36183

FORM 8-K

Filing date
09 Mar 2016
Reporting date
09 Mar 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
425 File 001-36183

FORM 8-K

Filing date
09 Mar 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36183

FORM 8-K

Filing date
29 Feb 2016
Reporting date
29 Feb 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
425 File 001-36183

FORM 8-K

Filing date
29 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-87931

SC 13G/A filing

Filing date
16 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-87931

CELLADON CORP

Filing date
16 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36183

FORM 8-K

Filing date
16 Feb 2016
Reporting date
16 Feb 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
425 File 001-36183

FORM 8-K

Filing date
16 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
424B3 File 333-208521

424B3

Filing date
16 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
CT ORDER File 333-208521

CT ORDER filing

Filing date
16 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-208521

EFFECT filing

Filing date
12 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-87931

SC 13G/A filing

Filing date
11 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-87931

SCHEDULE 13G AMENDMENT

Filing date
11 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36183

FORM 8-K

Filing date
10 Feb 2016
Reporting date
10 Feb 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
425 File 001-36183

FORM 8-K

Filing date
10 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
CORRESP

CORRESP filing

Filing date
10 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
CORRESP

CORRESP filing

Filing date
08 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
S-4/A File 333-208521

FORM S-4/A

Filing date
08 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
UPLOAD

UPLOAD filing

Filing date
08 Feb 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-87931

SC 13G

Filing date
29 Jan 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .